VFA
ADAP

Voya Financial Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Voya Financial Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-37,820
Closed -$290K – 625
2020
Q3 		$290K Buy
+37,820
New +$331K 0.01% 479

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Voya Financial Advisors's ADAP Position: Q4 2020 in Review

Voya Financial Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q4 2020, closing a stake of 37,820 shares — an estimated $290K sold.

Voya Financial Advisors first reported a position in ADAP in Q3 2020 and held it in 1 quarter. The position peaked at $290K in Q3 2020. 87 funds tracked by Wall St. Rank hold ADAP as of Q4 2020.

  • Voya Financial Advisors reported no remaining Adaptimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Voya Financial Advisors sold 37,820 Adaptimmune Therapeutics shares in Q4 2020, an estimated $290K.
  • Voya Financial Advisors first reported a position in Adaptimmune Therapeutics in Q3 2020 and held it in 1 quarter.
  • Voya Financial Advisors's Adaptimmune Therapeutics position peaked at $290K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2020.

Based on Voya Financial Advisors's 13F filing for Q4 2020, filed 5 Mar 2021.